金融界3月4日消息,有投资者在互动平台向丽珠集团提问:贵司与烟台迈百瑞,2016年达成协议共同开发ADC药物。还有在继续开发ADC药物吗?有无实质进展?
公司回答表示:基于HER2-ADC项目的市场前景和竞争格局的综合考量,公司已终止该项目后续推进。目前公司生物药平台已建立抗体类药物、重组蛋白药物、重组蛋白疫苗等特色技术平台,未来将合理配置资源,进一步聚焦优势项目的研发进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.